3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
4
Completed
2
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
2
Carcinoma
2
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
Cisplatin
12
Cetuximab
9
pembrolizumab
7
Radiotherapy
7
Fluorouracil
6
Carboplatin
5
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
epacadostat
3
Radiation
3
Docetaxel
3
Venlafaxine Hydrochloride
2
Surveys and Questionnaires
2
Panitumumab
2
Paclitaxel
2
Ketamine
2
zimberelimab
1
vandetanib
1
tislelizumab
1
temsirolimus
1
ruxolitinib
1
plerixafor
1
nimotuzumab
1
linrodostat
1
fosbretabulin
1
fluoromisonidazole
1
fludarabine phosphate
1
fludarabine
1
elgemtumab
1
ebselen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Head and Neck Neoplasms
×
nimotuzumab
×
Clear all
NCT01345084
2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3
Withdrawn